

Rosalie Liccardo Pacula

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5337063/publications.pdf>

Version: 2024-02-01

95
papers

5,752
citations

87888

38
h-index

88630

70
g-index

106
all docs

106
docs citations

106
times ranked

3996
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing the Effects of Medical Marijuana Laws on Marijuana Use: The Devil is in the Details. <i>Journal of Policy Analysis and Management</i> , 2015, 34, 7-31.	1.4	319
2	Association of State Recreational Marijuana Laws With Adolescent Marijuana Use. <i>JAMA Pediatrics</i> , 2017, 171, 142.	6.2	313
3	Do medical marijuana laws reduce addictions and deaths related to pain killers?. <i>Journal of Health Economics</i> , 2018, 58, 29-42.	2.7	248
4	Medical marijuana laws and adolescent marijuana use in the USA from 1991 to 2014: results from annual, repeated cross-sectional surveys. <i>Lancet Psychiatry</i> , 2015, 2, 601-608.	7.4	226
5	Does increasing the beer tax reduce marijuana consumption?. <i>Journal of Health Economics</i> , 1998, 17, 557-585.	2.7	218
6	Medical Marijuana and Marijuana Legalization. <i>Annual Review of Clinical Psychology</i> , 2017, 13, 397-419.	12.3	201
7	Developing Public Health Regulations for Marijuana: Lessons From Alcohol and Tobacco. <i>American Journal of Public Health</i> , 2014, 104, 1021-1028.	2.7	190
8	Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: Findings from state policy evaluations. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 644-663.	2.1	180
9	Association Between State Laws Facilitating Pharmacy Distribution of Naloxone and Risk of Fatal Overdose. <i>JAMA Internal Medicine</i> , 2019, 179, 805.	5.1	165
10	Medical marijuana laws and adolescent marijuana use in the United States: a systematic review and meta-analysis. <i>Addiction</i> , 2018, 113, 1003-1016.	3.3	142
11	Alcohol and marijuana use among college students: economic complements or substitutes?. <i>Health Economics (United Kingdom)</i> , 2004, 13, 825-843.	1.7	137
12	State Mental Health Parity Laws: Cause Or Consequence Of Differences In Use?. <i>Health Affairs</i> , 1999, 18, 182-192.	5.2	130
13	Marijuana Markets: Inferences from Reports by the Household Population. <i>Journal of Drug Issues</i> , 2006, 36, 173-200.	1.2	122
14	Supply-Side Drug Policy in the Presence of Substitutes: Evidence from the Introduction of Abuse-Deterrent Opioids. <i>American Economic Journal: Economic Policy</i> , 2018, 10, 1-35.	3.1	119
15	Marijuana Liberalization Policies: Why We Can't Learn Much from Policy Still in Motion. <i>Journal of Policy Analysis and Management</i> , 2014, 33, 212-221.	1.4	115
16	Why Changes in Price Matter When Thinking About Marijuana Policy: A Review of the Literature on the Elasticity of Demand. <i>Public Health Reviews</i> , 2013, 35, 1-18.	3.2	107
17	In the weeds: a baseline view of cannabis use among legalizing states and their neighbours. <i>Addiction</i> , 2016, 111, 973-980.	3.3	105
18	The effects of medical marijuana laws on potency. <i>International Journal of Drug Policy</i> , 2014, 25, 308-319.	3.3	102

#	ARTICLE	IF	CITATIONS
19	Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment. JAMA - Journal of the American Medical Association, 2016, 316, 1211.	7.4	99
20	Supply of buprenorphine waived physicians: The influence of state policies. Journal of Substance Abuse Treatment, 2015, 48, 104-111.	2.8	96
21	An Analysis of Applicants Presenting to a Medical Marijuana Specialty Practice in California. Journal of Drug Policy Analysis, 2011, 4, .	0.5	91
22	Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties. Milbank Quarterly, 2015, 93, 561-583.	4.4	89
23	What we can-and cannot-expect from school-based drug prevention. Drug and Alcohol Review, 2004, 23, 79-87.	2.1	88
24	A Population-Based Examination of Trends and Disparities in Medication Treatment for Opioid use Disorders among Medicaid Enrollees. Substance Abuse, 2018, 39, 419-425.	2.3	87
25	Considering Marijuana Legalization: Insights for Vermont and Other Jurisdictions. , 2015, , .		86
26	Prevalence of Cannabis Use in Youths After Legalization in Washington State. JAMA Pediatrics, 2019, 173, 192.	6.2	85
27	Marijuana use and high school dropout: the influence of unobservables. Health Economics (United Tj ETQq1 1 0.784314 rgBT /Overlo	1.7	80
28	Words Can Be Deceiving: A Review of Variation among Legally Effective Medical Marijuana Laws in the United States. Journal of Drug Policy Analysis, 2014, 7, 1-19.	0.5	80
29	Racial differences in marijuana-usersâ€™ risk of arrest in the United States. Drug and Alcohol Dependence, 2006, 84, 264-272.	3.2	78
30	Heterogeneity in the composition of marijuana seized in California. Drug and Alcohol Dependence, 2011, 117, 59-61.	3.2	77
31	Mapping medical marijuana: state laws regulating patients, product safety, supply chains and dispensaries, 2017. Addiction, 2017, 112, 2206-2216.	3.3	75
32	Lower-Risk Cannabis Use Guidelines (LRCUG) for reducing health harms from non-medical cannabis use: A comprehensive evidence and recommendations update. International Journal of Drug Policy, 2022, 99, 103381.	3.3	75
33	Design considerations for legalizing cannabis: lessons inspired by analysis of California's Proposition 19. Addiction, 2012, 107, 865-871.	3.3	62
34	State Medical Marijuana Laws: Understanding the Laws and Their Limitations. Journal of Public Health Policy, 2002, 23, 413.	2.0	57
35	Do Citizens Know Whether Their State Has Decriminalized Marijuana? Assessing the Perceptual Component of Deterrence Theory. Review of Law and Economics, 2009, 5, .	0.3	54
36	Understanding and learning from the diversification of cannabis supply laws. Addiction, 2017, 112, 1128-1135.	3.3	53

#	ARTICLE	IF	CITATIONS
37	Early Impacts of Marijuana Legalization: An Evaluation of Prices in Colorado and Washington. <i>Journal of Primary Prevention</i> , 2017, 38, 221-248.	1.6	44
38	The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use. <i>Addiction</i> , 2022, 117, 1510-1517.	3.3	44
39	Datapoints: Labor Force Participation by Persons With Mental Illness. <i>Psychiatric Services</i> , 1999, 50, 1407-1407.	2.0	43
40	College Students' Use of Cocaine. <i>Substance Use and Misuse</i> , 2006, 41, 489-509.	1.4	41
41	Risks and Prices: The Role of User Sanctions in Marijuana Markets. <i>B E Journal of Economic Analysis and Policy</i> , 2010, 10, .	0.9	38
42	How increasing medical access to opioids contributes to the opioid epidemic: Evidence from Medicare Part D. <i>Journal of Health Economics</i> , 2020, 71, 102286.	2.7	36
43	Bringing perspective to illicit markets: Estimating the size of the U.S. marijuana market. <i>Drug and Alcohol Dependence</i> , 2011, 119, 153-160.	3.2	33
44	THE EFFECTS OF MACRO-LEVEL INTERVENTIONS ON ADDICTIVE BEHAVIOR. <i>Substance Use and Misuse</i> , 2001, 36, 1901-1922.	1.4	32
45	Opioid analgesic and benzodiazepine prescribing among Medicaid-enrollees with opioid use disorders: The influence of provider communities. <i>Journal of Addictive Diseases</i> , 2017, 36, 14-22.	1.3	31
46	Marijuana and Youth. , 0, , 271-326.		31
47	Invisible wounds, visible savings? Using microsimulation to estimate the costs and savings associated with providing evidence-based treatment for PTSD and depression to veterans of Operation Enduring Freedom and Operation Iraqi Freedom.. <i>Psychological Trauma: Theory, Research, Practice, and Policy</i> , 2011, 3, 201-211.	2.1	30
48	Substance use and recessions: What can be learned from economic analyses of alcohol?. <i>International Journal of Drug Policy</i> , 2011, 22, 326-334.	3.3	29
49	A SUPPLYâ€ŚSIDE PERSPECTIVE ON THE OPIOID CRISIS. <i>Journal of Policy Analysis and Management</i> , 2018, 37, 438-446.	1.4	29
50	The Evolving Consequences of OxyContin Reformulation on Drug Overdoses. <i>American Journal of Health Economics</i> , 2021, 7, 41-67.	3.0	29
51	Letter: Economic modelling of the gateway effect. , 1997, 6, 521-524.		28
52	The state of the science in opioid policy research. <i>Drug and Alcohol Dependence</i> , 2020, 214, 108137.	3.2	26
53	The impacts of potency, warning messages, and price on preferences for Cannabis flower products. <i>International Journal of Drug Policy</i> , 2019, 74, 1-10.	3.3	25
54	State medical marijuana laws: understanding the laws and their limitations. <i>Journal of Public Health Policy</i> , 2002, 23, 413-39.	2.0	24

#	ARTICLE	IF	CITATIONS
55	Is the drug court model exportable? The cost-effectiveness of a driving-under-the-influence court. <i>Journal of Substance Abuse Treatment</i> , 2006, 31, 75-85.	2.8	21
56	Decomposing Racial Disparities in Prison and Drug Treatment Commitments for Criminal Offenders in California. <i>Journal of Legal Studies</i> , 2014, 43, 155-187.	0.4	19
57	Comparison of Medical Cannabis Use Reported on a Confidential Survey vs Documented in the Electronic Health Record Among Primary Care Patients. <i>JAMA Network Open</i> , 2022, 5, e2211677.	5.9	19
58	Natural Experiments in a Complex and Dynamic Environment: The Need for a Measured Assessment of the Evidence. <i>Journal of Policy Analysis and Management</i> , 2014, 33, 232-235.	1.4	18
59	Changes in Emergency Department Encounters for Vomiting After Cannabis Legalization in Colorado. <i>JAMA Network Open</i> , 2021, 4, e2125063.	5.9	18
60	Does the sunset of mental health parity really matter?. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2001, 28, 353-369.	2.1	16
61	Data Needs in Opioid Systems Modeling: Challenges and Future Directions. <i>American Journal of Preventive Medicine</i> , 2021, 60, e95-e105.	3.0	15
62	The price elasticity of demand for heroin: Matched longitudinal and experimental evidence. <i>Journal of Health Economics</i> , 2015, 41, 59-71.	2.7	14
63	Cannabis flower prices and transitions to legal sources after legalization in Canada, 2019-2020. <i>Drug and Alcohol Dependence</i> , 2022, 231, 109262.	3.2	14
64	Assessment of Recreational Cannabis Dispensaries' Compliance With Underage Access and Marketing Restrictions in California. <i>JAMA Pediatrics</i> , 2021, 175, 1178.	6.2	13
65	The incremental inpatient costs associated with marijuana comorbidity. <i>Drug and Alcohol Dependence</i> , 2008, 92, 248-257.	3.2	12
66	Relationships of Cannabis Policy Liberalization With Alcohol Use and Co-Use With Cannabis: A Narrative Review. <i>Alcohol Research: Current Reviews</i> , 2022, 41, 06.	3.6	12
67	A Systematic Review of the Prevention and Treatment of Prescription Drug Misuse. <i>Military Medicine</i> , 2016, 181, 410-423.	0.8	10
68	Cannabis and the Opioid Crisis. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 108-116.	2.9	10
69	Moving beyond the classic difference-in-differences model: a simulation study comparing statistical methods for estimating effectiveness of state-level policies. <i>BMC Medical Research Methodology</i> , 2021, 21, 279.	3.1	10
70	Impact of cannabis legalization on healthcare utilization for psychosis and schizophrenia in Colorado. <i>International Journal of Drug Policy</i> , 2022, 104, 103685.	3.3	10
71	Datapoints: Mental Health Parity and Employer-Sponsored Health Insurance in 1999-2000: I. Limits. <i>Psychiatric Services</i> , 2000, 51, 1361-1361.	2.0	9
72	Does Mandatory Diversion to Drug Treatment Eliminate Racial Disparities in the Incarceration of Drug Offenders? An Examination of California's Proposition 36. <i>Journal of Quantitative Criminology</i> , 2017, 33, 179-205.	2.9	9

#	ARTICLE	IF	CITATIONS
73	Current U.S. State Cannabis Sales Limits Allow Large Doses for Use or Diversion. <i>American Journal of Preventive Medicine</i> , 2021, 60, 701-705.	3.0	9
74	Datapoints: Mental Health Parity and Employer-Sponsored Health Insurance in 1999-2000: II. Copayments and Coinsurance. <i>Psychiatric Services</i> , 2000, 51, 1487-1487.	2.0	6
75	Building the data infrastructure to evaluate cannabis legalization. <i>Addiction</i> , 2017, 112, 1140-1141.	3.3	6
76	Advancing knowledge on cannabis policy using evidence from North America. <i>International Journal of Drug Policy</i> , 2017, 42, 36-38.	3.3	6
77	Cannabis legalization and cannabis-involved pregnancy hospitalizations in Colorado. <i>Preventive Medicine</i> , 2022, 156, 106993.	3.4	6
78	California Cannabis Marketsâ€™ Why Industry-Friendly Regulation Is Not Good Public Health. <i>JAMA Health Forum</i> , 2022, 3, e222018.	2.2	6
79	Internet search and medicaid prescription drug data as predictors of opioid emergency department visits. <i>Npj Digital Medicine</i> , 2021, 4, 21.	10.9	5
80	Did the dependent coverage expansion increase risky substance use among young adults?. <i>Drug and Alcohol Dependence</i> , 2017, 178, 556-561.	3.2	4
81	The need to more effectively regulate END markets: A primary public health lesson of the U.S. vaping associated lung injury outbreak. <i>Addiction</i> , 2021, 116, 994-995.	3.3	3
82	Claims-based measures of prescription opioid utilization: A practical guide for researchers. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109087.	3.2	3
83	The iCannToolkit: a tool to embrace measurement of medicinal and nonâ€™medicinal cannabis use across licit, illicit and crossâ€™cultural settings. <i>Addiction</i> , 2022, , .	3.3	3
84	Rating the comparative efficacy of state-level cannabis policies on recreational cannabis markets in the United States. <i>International Journal of Drug Policy</i> , 2022, 106, 103744.	3.3	3
85	Comparison of hospital claims and poison center data to evaluate health impact of opioids, cannabis and synthetic cannabinoids. <i>American Journal of Emergency Medicine</i> , 2022, 53, 150-153.	1.6	2
86	Limits of Current Economic Analyses of the Demand for Illicit Drugs. <i>Substance Use and Misuse</i> , 2006, 41, 607-609.	1.4	1
87	Do Citizens Know Whether Their State Has Decriminalized Marijuana? A Test of the Perceptual Assumption in Deterrence Theory. <i>SSRN Electronic Journal</i> , 2008, , .	0.4	1
88	State-Level Approaches to Expanding Pharmacistsâ€™ Authority to Dispense Naloxone May Affect Accessibilityâ€™ Reply. <i>JAMA Internal Medicine</i> , 2019, 179, 1443.	5.1	1
89	Commentary on Rychert and Wilkins (2021) â€™Why did New Zealand's referendum to legalise recreational cannabis fail?â€™. <i>Drug and Alcohol Review</i> , 2021, 40, 884-885.	2.1	1
90	Economic Analysis and Policy Studies: Special Challenges in the Prevention Sciences. , 2014, , 571-596.		1

#	ARTICLE	IF	CITATIONS
91	The Economic Modeling of the Gateway Effect. SSRN Electronic Journal, 0, , .	0.4	1
92	Addiction Research Centres and the Nurturing of Creativity. RAND's Drug Policy Research Center. Addiction, 2011, 106, 253-259.	3.3	0
93	RESPONSES TO QUESTIONS ON POLICING AND INSURANCE BENEFIT DESIGN AS THEY PERTAIN TO THE OPIOID CRISIS. Journal of Policy Analysis and Management, 2018, 37, 449-451.	1.4	0
94	Causes and Consequences of Illicit Drug Epidemics. , 2021, , 1-37.		0
95	Prices and Purchase Sources for Dried Cannabis Flower in the United States, 2019â€“2020. Cannabis and Cannabinoid Research, 2022, , .	2.9	0